Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1 clinical trials
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Part 2: Period A: Risankizumab or ustekinumab for 16 weeks. Period B: Risankizumab or no treatment for 36 weeks. Period C: Re-treatment with risankizumab for 16 weeks.

systemic therapy
ustekinumab
plaque psoriasis
risankizumab
inflammatory disease
  • 0 views
  • 19 Feb, 2024